Business Description
Deciphera Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US24344T1016
Description
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 11.83 | |||||
Equity-to-Asset | 0.74 | |||||
Debt-to-Equity | 0.07 | |||||
Debt-to-EBITDA | -0.12 | |||||
Interest Coverage | N/A | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 1.27 | |||||
Beneish M-Score | -1.82 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 36.5 | |||||
3-Year EBITDA Growth Rate | 20.1 | |||||
3-Year EPS without NRI Growth Rate | 21.8 | |||||
3-Year FCF Growth Rate | 26.6 | |||||
3-Year Book Growth Rate | -22.7 | |||||
Future 3-5Y Total Revenue Growth Rate | 12.1 |
Momentum Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 42.8 | |||||
9-Day RSI | 43.21 | |||||
14-Day RSI | 44.24 | |||||
6-1 Month Momentum % | 48.34 | |||||
12-1 Month Momentum % | 8.65 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 3.8 | |||||
Quick Ratio | 3.59 | |||||
Cash Ratio | 3.05 | |||||
Days Inventory | 2342.32 | |||||
Days Sales Outstanding | 57.01 | |||||
Days Payable | 2042.55 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -11.8 | |||||
Shareholder Yield % | -12.4 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 97.72 | |||||
Operating Margin % | -129.14 | |||||
Net Margin % | -119.34 | |||||
FCF Margin % | -90.39 | |||||
ROE % | -50.8 | |||||
ROA % | -39.24 | |||||
ROIC % | -187.89 | |||||
ROC (Joel Greenblatt) % | -521.34 | |||||
ROCE % | -51.72 |
GF Value Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 7.64 | |||||
PB Ratio | 3.36 | |||||
Price-to-Tangible-Book | 3.37 | |||||
EV-to-EBIT | -4.29 | |||||
EV-to-EBITDA | -4.33 | |||||
EV-to-Revenue | 5.54 | |||||
EV-to-Forward-Revenue | 4.84 | |||||
EV-to-FCF | -6.13 | |||||
Price-to-Net-Current-Asset-Value | 4.56 | |||||
Price-to-Net-Cash | 6.42 | |||||
Earnings Yield (Greenblatt) % | -23.31 | |||||
FCF Yield % | -12.45 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Deciphera Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 151.463 | ||
EPS (TTM) (€) | -2.124 | ||
Beta | 0.3 | ||
Volatility % | 40.78 | ||
14-Day RSI | 44.24 | ||
14-Day ATR (€) | 0.313205 | ||
20-Day SMA (€) | 13.978 | ||
12-1 Month Momentum % | 8.65 | ||
52-Week Range (€) | 9.512 - 15.94 | ||
Shares Outstanding (Mil) | 80.8 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Deciphera Pharmaceuticals Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Deciphera Pharmaceuticals Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Deciphera Pharmaceuticals Inc Frequently Asked Questions
What is Deciphera Pharmaceuticals Inc(FRA:D05)'s stock price today?
When is next earnings date of Deciphera Pharmaceuticals Inc(FRA:D05)?
Does Deciphera Pharmaceuticals Inc(FRA:D05) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |